Technical

Technical — The Price Picture

After a 10-bagger run from the 2020 lows to a ₹267 peak in late 2021, Lyka Labs is now mid-unwind. The stock sits 78% below that all-time high, 54% below its 52-week high, 31% below its 200-day moving average, and has just printed its second death cross in twelve months. The fundamentals say "microcap pharma trying to turn a corner"; the price action says distribution is still in force. The charts are also fighting a structural handicap the reader should note first — this is a thinly-traded ₹200-crore BSE/NSE microcap where 50-day average volume has oscillated between 150 and 35,000 shares over the past year. Technicals here are directional, not tradable-to-three-decimals.

Illiquidity caveat. Recent 50-day average volume runs around 6,000 shares; single-day prints swing from zero to 35,000. RSI, MACD and Bollinger signals are still meaningful because they aggregate weeks of data, but intraday levels should be treated as approximate. Bid-ask cost of a scaled-in position is material.

1 — Snapshot

Beta versus the MSCI India ETF is only 0.53 — this stock does not move with the index. Its return stream is driven by idiosyncratic flow in a very shallow order book, which is exactly why the drawdown has continued while the broader Indian market has re-rated over the past quarter.

2 — The critical chart: 10-year price vs 50 and 200-day moving averages

Current price ₹58.16 is below the 200-day SMA of ₹84.56 — roughly 31% under. The structural picture is a textbook topping-then-distribution pattern: a parabolic 10x move from ₹17 (April 2020) to ₹229 (December 2021), a grinding sideways-to-down range through 2022–23, a renewed attempt in late 2024 that peaked at ₹154 in August, and a fresh leg down since February 2025 that has re-broken the 200-day on the way to new 12-month lows.

3 — Relative strength: Lyka vs India market vs US market (5-year rebase)

Even after the 55% drawdown from the 2024 high, Lyka is still +120% on a 5-year rebase — well ahead of INDA (+20%) and SPY (+80%). That is the memory of the 2021 retail-mania rally; none of that alpha has been given back to flat, but the 2025 behaviour is clearly lagging — Lyka has fallen 45% YTD while INDA is up low single digits. Relative strength is broken and still breaking. India pharma sector ETF was not available in the data — broad-market INDA is the only benchmark. For context against peers, see the Numbers tab.

4 — Momentum: RSI(14) and MACD histogram, last 18 months

RSI is 53 today — neutral, but that masks a violent round-trip: four separate visits below 30 (February, March, August and November 2025, plus February/March 2026) and only two brief overbought pops in the entire window. That repeated-oversold-without-overbought footprint is the defining signature of a downtrend. The MACD histogram has just flipped positive in the last two weeks after five months of sub-zero readings — the shortest-term momentum signal is green, but the medium-term momentum regime is still negative (MACD line at −0.30 is well below zero).

5 — Volume and conviction

Two patterns stand out. First, baseline volume collapsed by ~80% from April 2025 (~13,000 shares/day) through November 2025 (~1,500 shares/day) — a disengagement that typically precedes a capitulation event. Second, volume has spiked 5–20x above the 50-day average on the way down in March 2026 (the 22,843-share print on 17 March and 35,362-share print on 23 March) — distribution, not accumulation. Volume is siding with the bears.

All three of the top historical volume events were upside prints that marked local tops within 0–4 months — which is precisely the concern about the current March 2026 volume expansion happening on the downside.

6 — Volatility regime

30-day realized volatility just jumped to 78% — above the 5-year 80th percentile of 61% and deep in the top decile of history. Volatility spikes like this coincided with the August 2024 peak (~77%) and the June 2022 drawdown (~76%). High volatility at the tail of a downtrend with negative MACD and a fresh death cross typically resolves with either a capitulation low or a base-building pause; it almost never resolves into a clean breakout. ATR(14) of ₹4.21 on a ₹58 stock is a 7% daily range — position-sizing must reflect this.

7 — Technical scorecard and stance

Net score: −5 out of a possible +6. The tape is bearish.

Stance (3–6 month horizon)

Bearish. Lyka Labs is trending, momentum-weak, volume-weak, and over-volatile — every dimension except one (a two-week MACD histogram flip) is siding with the sellers. The fact that a 12-month price halving has failed to generate a single weekly oversold RSI bounce that sticks tells you there is still distribution to absorb. Until a catalyst emerges in the fundamentals (the Numbers tab flagged cash conversion as the single metric that would re-rate this stock), technical buyers will keep fading rallies.

Two levels define the view:

• Invalidates bearish stance: close above ₹84 (reclaim of the 200-day SMA). At that point trend, momentum and MA structure would all flip net-positive in one move, and the death cross would be on track to reverse within ~6–8 weeks.
• Confirms bearish stance: close below ₹44 (break of the 52-week low). A weekly close under ₹44 targets the 2020 Covid low and puts the structural 5-year uptrend in jeopardy, at which point realized volatility is likely to print a capitulation spike into 90%+.

In between, the base case is sideways grind in a ₹50–₹75 range until cash-flow data or a bulk-deal print changes the flow picture. Long-horizon investors waiting for the Numbers-tab re-rate have time — technicals suggest no urgency to buy before ₹50 is re-tested or ₹84 is reclaimed.